{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
When is the next results date for Parnax Lab Ltd?
The next results date for Parnax Lab Ltd is 13 February 2026.
Parnax Lab Ltd Upgraded to Hold by MarketsMOJO Amid Technical and Financial Improvements
Parnax Lab Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 1 February 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite some lingering challenges in long-term fundamentals and recent market underperformance.
Parnax Lab Ltd Downgraded to Sell Amid Technical Weakness and Valuation Concerns
Parnax Lab Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 January 2026. This revision reflects a combination of deteriorating technical indicators, subdued financial trends, and valuation concerns despite some positive quarterly performance. The company’s current Mojo Score stands at 34.0, with a Sell grade, signalling caution for investors amid a challenging market backdrop.
Parnax Lab Ltd Upgraded to Hold by MarketsMOJO on Improved Technicals and Valuation
Parnax Lab Ltd has seen its investment rating upgraded from Sell to Hold as of 22 January 2026, reflecting a notable improvement in its technical outlook and valuation metrics. Despite recent underperformance relative to the broader market, the company’s financial trends and quality parameters have shown signs of stabilisation, prompting a reassessment of its investment potential.
Parnax Lab Ltd is Rated Hold
Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with the latest insights into its performance and outlook.
Parnax Lab Ltd is Rated Hold
Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Parnax Lab Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Parnax Lab, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by evolving technical indicators and recent financial disclosures. While the stock’s recent price movements and quarterly results present a complex picture, the changes in evaluation metrics reflect a nuanced view of its current standing within the industry.
Parnax Lab’s Market Assessment Reflects Mixed Signals Amidst Technical Weakness
Parnax Lab, a player in the Pharmaceuticals & Biotechnology sector, has experienced a shift in market evaluation driven primarily by technical indicators, despite showing some positive financial metrics in recent quarters. The stock’s performance over the past year contrasts sharply with broader market trends, prompting a reassessment of its investment profile across quality, valuation, financial trends, and technical outlook.
Why is Parnax Lab falling/rising?
On 05-Dec, Parnax Lab Ltd’s stock price fell by 2.96% to close at ₹116.50, reflecting a continuation of its recent downward trend and underperformance relative to the broader market and its sector peers.
Parnax Lab Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Parnax Lab, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators, financial performance, valuation metrics, and broader market trends. This article analyses the key factors influencing the recent shift in the company’s assessment and what it means for investors navigating the current market environment.
How has been the historical performance of Parnax Lab?
Parnax Lab has shown steady growth in net sales and profitability, with net sales reaching 187.74 Cr in March 2025, up from 163.03 Cr in March 2022. Key financial metrics, including profit after tax and earnings per share, have also improved, reflecting a positive trend in overall performance.
Parnax Lab’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts
Parnax Lab, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This article analyses the recent shifts across four critical parameters shaping the company’s current market standing.
Are Parnax Lab latest results good or bad?
Parnax Lab's latest results show strong revenue growth with net sales of ₹62.60 crores, a 29.45% year-on-year increase, but profitability is a concern due to a declining operating profit margin and a drop in return on equity. Overall, while revenue momentum is positive, the company faces challenges in cost management and profitability.
How has been the historical performance of Parnax Lab?
Parnax Lab has shown steady financial growth, with net sales increasing from INR 89.52 crore in March 2021 to INR 187.74 crore in March 2025, and profit after tax rising from a loss of INR 2.92 crore in March 2020 to a profit of INR 11.54 crore in March 2025. The company has also improved its operating profit and cash flow significantly during this period.
Parnax Lab Q2 FY26: Strong Revenue Surge Masks Margin Pressures
Parnax Lab Limited, a micro-cap pharmaceutical formulations manufacturer, reported mixed results for Q2 FY26, with net profit rising 11.01% quarter-on-quarter to ₹3.63 crores but declining 6.45% year-on-year from ₹3.41 crores in Q2 FY25. The company's market capitalisation stands at ₹155.00 crores, with shares trading at ₹129.55 as of November 17, 2025.
How has been the historical performance of Parnax Lab?
Parnax Lab has shown steady financial improvement from March 2021 to March 2025, with net sales increasing from INR 89.52 crore to INR 187.74 crore, and profit before tax rising from a loss to INR 15.67 crore. The company also improved its operating profit and cash flow, indicating overall positive performance trends.
Is Parnax Lab overvalued or undervalued?
As of November 10, 2025, Parnax Lab is considered an attractive investment opportunity due to its undervalued status with a PE ratio of 13.34 and strong financial ratios, despite a year-to-date stock decline of 25.27%.
Is Parnax Lab overvalued or undervalued?
As of November 7, 2025, Parnax Lab is fairly valued with a PE ratio of 13.60 and an EV to EBITDA of 8.35, despite a 29.90% decline in stock performance over the past year, contrasting with a strong 5-year return of 575.46%.
Is Parnax Lab overvalued or undervalued?
As of November 7, 2025, Parnax Lab is fairly valued with a PE ratio of 13.60 and an EV to EBITDA of 8.35, making it more attractive than overvalued peers like Elitecon International and MMTC, despite a year-to-date decline of -23.81% compared to the Sensex's 6.50%, while maintaining a strong 5-year return of 575.46%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
